Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.5280
-0.0030 (-0.56%)
At close: Aug 13, 2025, 4:00 PM
0.5410
+0.0130 (2.46%)
Pre-market: Aug 14, 2025, 8:39 AM EDT
RANI Revenue
Rani Therapeutics Holdings had revenue of $1.20M in the twelve months ending June 30, 2025. In the year 2024, Rani Therapeutics Holdings had annual revenue of $1.03M.
Revenue (ttm)
$1.20M
Revenue Growth
n/a
P/S Ratio
14.47
Revenue / Employee
$11,321
Employees
106
Market Cap
37.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RANI News
- 6 days ago - Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery - GlobeNewsWire
- 3 months ago - Rani Therapeutics Announces Research Agreement with Chugai - GlobeNewsWire
- 3 months ago - Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 4 months ago - Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewsWire
- 5 months ago - Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - GlobeNewsWire